Valeant Pharma (VRX) Sees 'Dead Cat Bounce' after CEO Hit with Margin Call
Valeant Pharma (NYSE: VRX) is pushing to the highs of the session, following earlier news that about 1.3 million shares CEO Mike Pearson had pledged on a loan were sold yesterday due to margins calls.
The news suggests that some of the overhang in the market has now been alleviated.
Shares of Valeant last traded up 5%, however, they remain down nearly 60% since short seller Citron Research's initial short report on September 28th, which was followed by the 'smoking gun' report on October 21.
The company's entire Philidor-like specialty pharmacy business model is now in question and the U.S. Congress has its sights set on the company's drug pricing model.
Still, shares are seen as inexpensive on a sum-of-the-parts basis. Analysts at Mizuho yesterday suggested that looking at liquidation value using a DCF analysis of the business under catastrophic scenarios it generated a per-share value of $100.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Risk/reward skewed towards lower rates - UBS
- Can Boeing overcome struggles? Analysts see 'path back to normal' after earnings
- Can Boeing overcome struggles? Analysts see 'path back to normal' after earnings
Create E-mail Alert Related Categories
Insiders' Blog, Short Sales, Trader TalkRelated Entities
Citron ResearchSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!